Clinical Trial Update: Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus [Phase 1]

View source ↗

Summary

Amgen conducted a Phase 1 safety study of AMG 811 in subjects with discoid lupus erythematosus, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Discoid Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• AMG 811

Snippet

Sponsor: Amgen | Conditions: Cutaneous Lupus, Discoid Lupus | Phase 1 | Status: TERMINATED